Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 5/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321296 | 0.92 | GPR139 (0.44) | KCNQ3KCNQ2GPR139MCHR1L3MBTL1 | |
| SCHEMBL1322618 | 0.92 | GPR139 (0.43) | KCNQ3KCNQ2GPR139MCHR1L3MBTL1 | |
| SCHEMBL1320899 | 0.90 | GPR139 (0.42) | KCNQ3KCNQ2GPR139MCHR1L3MBTL1 | |
| SCHEMBL1321730 | 0.90 | KCNQ3 (0.48) | KCNQ3KCNQ2GABRA1GABRB2 | |
| SCHEMBL1319870 | 0.89 | KCNQ3 (0.49) | KCNQ3KCNQ2MCHR1L3MBTL1GSK3B | |
| SCHEMBL1322175 | 0.89 | KCNQ3 (0.43) | KCNQ3KCNQ2GPR139MCHR1 | |
| SCHEMBL1320359 | 0.89 | MCHR1 (0.46) | KCNQ3KCNQ2GPR139MCHR1ALOX5 | |
| SCHEMBL1320339 | 0.88 | GPR139 (0.41) | KCNQ3KCNQ2GPR139MCHR1L3MBTL1 | |
| SCHEMBL1321221 | 0.87 | GPR139 (0.43) | KCNQ3KCNQ2GPR139MCHR1ALOX5 | |
| SCHEMBL1321313 | 0.87 | KCNQ3 (0.48) | KCNQ3KCNQ2GPR139MCHR1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049061-A1 | SMALL MOLECULES AS KCNQ2/3 (KV7.2/3) CHANNEL ACTIVATORS AND THEIR MEDICAL USE THEREOF | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2026-02-19 | — | — | US | disclosed |
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | ICAGEN INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8431608-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2536718-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8058274-B2 | Heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2011102964-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143889-A1 | Heterocycles As Potassium Channel Modulators | KCNK10, KCNK9, KCNJ2 | KCNQ3 29/4885KCNQ2 7/4885GPR139 965/4885 |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | KCNQ3 23/4885KCNQ2 7/4885GPR139 1384/4885 |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | KCNQ3 23/4885KCNQ2 7/4885GPR139 1384/4885 |
| US-20260049061-A1 | SMALL MOLECULES AS KCNQ2/3 (KV7.2/3) CHANNEL ACTIVATORS AND THEIR MEDICAL USE THEREOF | KCNN3, KCNA7, KCNQ3 | KCNQ3 3/4885KCNQ2 8/4885GPR139 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.